Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CDK4 | P11802 | 3/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.44 |
| ▸ | CCND1 | P24385 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039846 | 1.00 | CDK1 (0.44) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL19836463 | 0.84 | CDK4 (0.59) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL30039843 | 0.84 | CDK4 (0.59) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL19836330 | 0.81 | CDK1 (0.51) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL30039856 | 0.81 | CDK1 (0.51) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL20987211 | 0.81 | CDK4 (0.51) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL22163943 | 0.81 | CDK4 (0.40) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL30040781 | 0.75 | GABRA1 (0.35) | CDK4KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL30038555 | 0.75 | MAPK14 (0.42) | CDK1CDK4CCNB1CCND1EGFR | |
| SCHEMBL19836336 | 0.75 | MAPK14 (0.42) | CDK1CDK4CCNB1CCND1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-113382991-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-113382991-A | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
| CN-110818690-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2020151742-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-07-30 | — | — | WO | disclosed |
| CN-110818690-A | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-108602802-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3492462-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| WO-2018019204-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | LCK, WEE1, JAK1 | CDK1 39/4885CDK4 83/4885CCNB1 577/4885 |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | LCK, WEE1, JAK1 | CDK1 39/4885CDK4 83/4885CCNB1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.